The BRAF V600E mutation is well known for its role in melanoma, and BRAF inhibitors such as dabrafenib have already been shown to be fairly effective in advanced CRCs with the BRAF V600E mutation in clinical studies.25 This evidence concerns the gene BRAF and melanoma.